68Ga-前列腺特异性膜抗原PET/CT在子宫内膜癌中的应用:初步报告
这项前瞻性先导研究纳入7例子宫内膜癌患者,术前注射2 MBq/kg 68Ga-PSMA-11后60分钟行PET/CT,6/7例PET/CT阳性且组织病理学证实子宫内膜癌;组织病理分期与ceCT、MR、68Ga-PSMA-11 PET/CT分期一致分别为4/7、6/7、5/7,三种方法分期均一致3/7例;作者认为初步经验显示68Ga-PSMA-11用于子宫内膜癌患者的可能性,但需前瞻性大型研究探索其真实诊断作用。
要点
- 7例子宫内膜癌患者术前接受68Ga-PSMA-11 PET/CT,6/7例图像阳性并经组织病理学证实为子宫内膜癌。
- 68Ga-PSMA-11 PET/CT分期与组织病理分期一致5/7例,MR一致6/7例,ceCT一致4/7例。
- 三种方法分期均一致3/7例;作者认为需前瞻性大型研究探索PSMA的真实诊断作用。
核心结论
- 初步经验显示68Ga-PSMA-11用于子宫内膜癌患者的可能性,但需前瞻性大型研究探索放射性标记PSMA在该领域的真实诊断作用。
研究设计与样本
- 前瞻性先导研究,纳入7例拟行手术治疗的子宫内膜癌女性患者,平均年龄58±7.9岁。
- 所有患者均接受经阴道超声、胸部及腹部增强CT和MRI等标准影像检查,并另行在注射2 MBq/kg 68Ga-PSMA-11后60分钟于Siemens Biograph扫描仪上行PET/CT。
- 研究经华沙医科大学伦理委员会批准(KB/2/A/2018)。
主要发现
- 7例患者中6例68Ga-PSMA-11 PET/CT图像阳性,组织病理学证实为子宫内膜癌。
- 1例患者左卵巢出现摄取,最终组织病理学显示为出血性囊肿。
- 增强CT与68Ga-PSMA-11融合后进一步确认淋巴结受累。
- 组织病理分期与增强CT分期一致4/7例,与MR一致6/7例,与68Ga-PSMA-11 PET/CT一致5/7例。
- 所有方法在分期上均一致的患者为3/7例。
关键数值与推荐
- 注射剂量为2 MBq/kg 68Ga-PSMA-11,注射后60分钟采集PET/CT。
- 组织病理分期与各方法分期一致例数:增强CT 4/7、MR 6/7、68Ga-PSMA-11 PET/CT 5/7。
- 所有方法分期均一致3/7例。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文结论指出需前瞻性大型研究来探索放射性标记PSMA在子宫内膜癌领域的真实诊断作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE OF THE REPORT: Endometrial cancer is the most common gynecological cancer. Prostate-specific membrane antigen (PSMA) is expressed in prostate cancer cells but can be found in other cancers, such as endometrial cancer, during angiogenesis.The aim of this prospective pilot study was to evaluate the feasibility of using 68Ga-PSMA-11 PET/CT in endometrial cancer patients before surgical treatment. PATIENTS AND METHODS: Seven women with a mean age of 58 ± 7.9 years were included in the study. All patients underwent standard imaging studies involving transvaginal ultrasound, ceCT scans of the chest and abdomen, and MRI as qualified for surgery. Additionally, PET/CT was performed on a Siemens Biograph scanner 60 minutes after the injection of 2 MBq/kg 68Ga-PSMA-11. RESULTS: Six of 7 patients had positive 68Ga-PSMA-11 PET/CT images, and histopathology confirmed endometrial cancer. One patient also exhibited uptake in the left ovary, and final histopathology revealed a hemorrhagic cyst. Lymph node involvement was further confirmed after ceCT fusion with 68Ga-PSMA-11. The consensus of histopathological staging of endometrial cancer and ceCT was 4/7, that of MR was 6/7, and that of 68Ga-PSMA-11 PET/CT was 5/7. All methods were consistent in terms of staging in 3/7 patients. CONCLUSIONS: The initial experience showed the possibility of using 68Ga-PSMA-11 in endometrial cancer patients. However, prospective large studies are needed to explore the real diagnostic role of radiolabelled PSMA in this field.This study was approved by the Ethical Committee of the Medical University of Warsaw (KB/2/A/2018).
引用
- Kunikowska J, Pełka K, Bizoń M, et al. 68Ga-Prostate-Specific Membrane Antigen PET/CT in Endometrial Cancer: A Preliminary Report. Clin Nucl Med. 2024. PMID: 39485875. doi:10.1097/RLU.0000000000005446
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。